Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2008-05-20
2008-05-20
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S192100, C514S002600, C514S012200, C530S350000, C536S023400
Reexamination Certificate
active
07374757
ABSTRACT:
Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
REFERENCES:
patent: 5712380 (1998-01-01), Kendall et al.
patent: 6011003 (2000-01-01), Charnock-Jones et al.
patent: 6100071 (2000-08-01), Davis-Smyth et al.
patent: 2005/0043236 (2005-02-01), Daly et al.
patent: 2006/0058234 (2006-03-01), Daly et al.
patent: WO97/44453 (1997-11-01), None
patent: WO98/13071 (1998-04-01), None
patent: WO99/03996 (1999-01-01), None
Terman, B. I., et al, “Identification of a new endothelial cell growth factor receptor tyrosine kinase”, Oncogene (1991) 6:1677-1683.
Terman, B.I., et al, “Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor”, Biochem Biophys Res Comm (1992) 187(3):1579-1586.
Tsutsumi, Y., et al, “PEGylation of interleukin-6 effectively increases its thrombopoietic potency”, Thrombosis and Haemostasis (1997) 77(1):168-173.
Dunca, R. and Spreafico, F., “Polymer Conjugates”, Drug Delivery Systems (1994) 27(4):290-306.
Hileman, R.E., et al., “Glycosaminoglycan-protein interactions: definitions of consensus sites in glycosaminoglycan binding proteins”, BioEssays (1998) 20:156-167.
deVries, Carlie, et al., “Thefms-like tyrosine kinase, a receptor for vascular endothelial growth factor”, Science (1992) 225:989-991.
Sharifi, J., et al., “Improving monoclonal antibody pharmacokinetics via chemical modification”, Quart J Nucl Med (1998) 42:242-249.
Jensen-Pippo, K.E., et al., “Enteral bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol)”, (1996) Pharm Res 13(1):102-107.
Tanaka, K., et al., “Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 Tyrosine kinase)”, (1997) Jpn J Cancer Res 88:867-876.
Yang, J.C., et al., “The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma”, (1995) Cancer 76(4): 687-694.
Davis-Smyth, T., et al., 1996, “The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade”, The EMBO Journal 15(18):4919-4927.
Davis Samuel
Papadopoulos Nicholas J.
Yancopoulos George D.
Lockard Jon M
Regeneron Pharmaceuticals Inc.
Saoud Christine J
Valeta, Esq. Gregg
LandOfFree
Modified chimeric polypeptides with improved pharmacokinetic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified chimeric polypeptides with improved pharmacokinetic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified chimeric polypeptides with improved pharmacokinetic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2750701